文献速递胸部肿瘤放疗姑息放疗与转移瘤

晚期非小细胞肺癌姑息放疗相关淋巴细胞减少研究

Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-02-19

多因素分析显示胸部平均放疗剂量、基线淋巴细胞和糖皮质激素使用与≥G3淋巴细胞减少风险显著相关;≥G3淋巴细胞减少与总生存无关,而CRP/白蛋白比值>0.12和糖皮质激素使用独立与较差总生存相关。

要点

  • 胸部平均放疗剂量高、基线淋巴细胞低和糖皮质激素使用增加≥G3淋巴细胞减少风险。
  • ≥G3淋巴细胞减少未显示与较差总生存相关。
  • CRP/白蛋白比值>0.12和糖皮质激素使用独立预测较差总生存。

核心结论

  • 胸部平均放疗剂量高增加≥G3淋巴细胞减少风险,限制胸部剂量体积可能有助于预防严重淋巴细胞减少。
  • ≥G3淋巴细胞减少与较差总生存无关,但高基线CRP/白蛋白比值与较差总生存相关,可能是晚期NSCLC姑息放疗的预后因素。

研究设计与样本

  • 通过规划CT上-500至1200 HU窗获取胸部感兴趣体积(包括胸部软组织和骨小梁),计算胸部VOI及其他区域(肺、椎体)的剂量参数。
  • 使用Logistic回归分析≥G3淋巴细胞减少与治疗参数的关系,使用Log-rank和Cox模型评估总生存与放疗剂量参数、基线血细胞计数和蛋白水平及临床因素的关系。

主要发现

  • 多因素分析中,胸部平均放疗剂量(OR 1.67;p=0.04)、基线淋巴细胞(OR 0.65;p=0.01)和糖皮质激素使用(OR 6.07;p=0.02)与≥G3淋巴细胞减少风险增加显著相关。
  • 单因素分析中,较差总生存与高胸部平均放疗剂量、高CRP/白蛋白比值、大肿瘤体积和糖皮质激素使用相关(p<0.05),但与≥G3淋巴细胞减少无关。
  • CRP/白蛋白比值>0.12(HR 2.28,p=0.03)和糖皮质激素使用(HR 2.52,p=0.01)独立与较差总生存相关。

关键数值与推荐

  • ≥G3淋巴细胞减少依据CTCAE v4.0定义(淋巴细胞最低点)。
  • CRP/白蛋白比值>0.12为独立预后因素(HR 2.28,p=0.03)。
  • 糖皮质激素使用为独立预后因素(HR 2.52,p=0.01)。

临床怎么用

  • 对接受姑息性分次放疗的晚期NSCLC患者,可考虑限制胸部放疗剂量体积以降低严重淋巴细胞减少风险。
  • 基线CRP/白蛋白比值>0.12和糖皮质激素使用可提示较差总生存,可作为预后评估参考。

局限性

  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphopenia during radiotherapy (RT) may have an adverse effect on treatment outcome. The aim of this study is to investigate associations between lymphopenia and RT parameters in patients with advanced lung cancer. Moreover, to investigate the prognostic role of lymphopenia, blood protein levels, and treatment and patient-related factors. MATERIAL AND METHODS: Sixty-two advanced stage non-small cell lung cancer (NSCLC) patients were retrospectively analyzed. Blood counts were available prior to, during, and after RT (3Gyx10). For each patient, a thoracic volume of interest (VOI) -including thoracic soft tissue and trabecular bone- was obtained by applying a CT window of -500 to 1200 HU in the planning CT. Dose parameters from thoracic VOI and other regions including lungs and vertebrae were calculated. Association between risk of lymphopenia ≥ G3 (lymphocytes at nadir according to CTCAE v4.0) and therapeutic parameters was investigated using Logistic regression. Relationships between overall survival (OS) and RT dose parameters, baseline blood counts and protein levels, and clinical factors were evaluated using Log-rank and Cox models. RESULT: Mean thoracic RT dose (odds ratio [OR] 1.67; p = 0.04), baseline lymphocytes (OR 0.65; p = 0.01), and corticosteroids use (OR 6.07; p = 0.02) were significantly associated with increased risk of lymphopenia ≥ G3 in multivariable analysis. Worse OS was associated with high mean thoracic RT dose, high CRP/Albumin, large tumor volume and corticosteroids use (p < 0.05, univariate analysis), but not with lymphopenia ≥ G3. CRP/Albumin ratio > 0.12 (hazard ratio [HR] 2.28, p = 0.03) and corticosteroid use (HR 2.52, p = 0.01) were independently associated with worse OS. CONCLUSION: High thoracic RT dose gave a higher risk of lymphopenia ≥ G3; hence limiting dose volume to the thorax may be valuable in preventing severe lymphopenia for patients receiving palliative fractionated RT. Still, lymphopenia ≥ G3 was not associated with worse OS. however, high baseline CRP/Albumin was associated with poorer OS and may carry important information as a prognostic factor of OS in advanced NSCLC receiving palliative RT.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Abravan A, Eide HA, Helland Å, et al. Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy. Clin Transl Radiat Oncol. 2020. PMID: 32181373. doi:10.1016/j.ctro.2020.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。